It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Simply Wall St
June 01, 2021
Source: Shutterstock

We have been pretty impressed with the performance at Amedisys, Inc. (NASDAQ:AMED) recently and CEO Paul Kusserow deserves a mention for their role in it. Coming up to the next AGM on 08 June 2021, shareholders would be keeping this in mind. It is likely that the focus will be on company strategy going forward as shareholders hear from the board and cast their votes on resolutions such as executive remuneration and other matters. In light of the great performance, we discuss the case why we think CEO compensation is not excessive.

Check out our latest analysis for Amedisys

Comparing Amedisys, Inc.'s CEO Compensation With the industry

Our data indicates that Amedisys, Inc. has a market capitalization of US$8.4b, and total annual CEO compensation was reported as US$6.4m for the year to December 2020. Notably, that's a decrease of 50% over the year before. While this analysis focuses on total compensation, it's worth acknowledging that the salary portion is lower, valued at US$900k.

On comparing similar companies from the same industry with market caps ranging from US$4.0b to US$12b, we found that the median CEO total compensation was US$6.5m. This suggests that Amedisys remunerates its CEO largely in line with the industry average. What's more, Paul Kusserow holds US$98m worth of shares in the company in their own name, indicating that they have a lot of skin in the game.

Component20202019Proportion (2020)
Salary US$900k US$899k 14%
Other US$5.5m US$12m 86%
Total CompensationUS$6.4m US$13m100%

Speaking on an industry level, nearly 19% of total compensation represents salary, while the remainder of 81% is other remuneration. Amedisys pays a modest slice of remuneration through salary, as compared to the broader industry. If total compensation is slanted towards non-salary benefits, it indicates that CEO pay is linked to company performance.

NasdaqGS:AMED CEO Compensation June 2nd 2021

Amedisys, Inc.'s Growth

Over the past three years, Amedisys, Inc. has seen its earnings per share (EPS) grow by 70% per year. In the last year, its revenue is up 6.9%.

Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's also good to see modest revenue growth, suggesting the underlying business is healthy. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.

Has Amedisys, Inc. Been A Good Investment?

We think that the total shareholder return of 220%, over three years, would leave most Amedisys, Inc. shareholders smiling. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.

To Conclude...

Given the company's decent performance, the CEO remuneration policy might not be shareholders' central point of focus in the AGM. However, investors will get the chance to engage on key strategic initiatives and future growth opportunities for the company and set their longer-term expectations.

CEO compensation is a crucial aspect to keep your eyes on but investors also need to keep their eyes open for other issues related to business performance. That's why we did some digging and identified 1 warning sign for Amedisys that you should be aware of before investing.

Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.

If you decide to trade Amedisys, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.